Clinical Trials Logo

Carcinoma, Squamous Cell clinical trials

View clinical trials related to Carcinoma, Squamous Cell.

Filter by:

NCT ID: NCT03468218 Active, not recruiting - Clinical trials for Recurrent Head and Neck Squamous Cell Carcinoma

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Start date: September 18, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab and cabozantinib in treating patients with head and neck squamous cell cancer that has come back or spread to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the pathways needed for cell growth. Giving pembrolizumab and cabozantinib may improve the chances of tumor response in patients with head and neck squamous cell cancer.

NCT ID: NCT03450967 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC

Start date: April 11, 2018
Phase: Phase 2
Study type: Interventional

- Clinical Phase: phase II single arm study - Primary Objectives: Response rate - Number of Subjects: 27 patients - Study Population: recurrent or metastatic head and neck squamous cell carcinoma - Investigational Product(s), Dose, and Mode of Administration: Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.). Proton therapy 5 GyE x 5 fractions - Study Assessments and Criteria for Evaluation: Safety Assessments: according to NCI CTCAE version 4.0 Efficacy Assessments: according to RECIST version 1.1 - Statistical Methods and Data Analysis: PFS: from the date of treatment to the date of progression or death or last follow-up OS: from the date of treatment to the date of death or last follow-up - Sample Size Determination: Patients must have a histologically confirmed diagnosis of HNSCC. In this phase II study, up to approximately 27 eligible patients will be enrolled. It is anticipated that full accrual to this study will take approximately 24 months. H0: Objective response rate ≤10% H1: Objective response rate ≥35% According to Simon's two-stage optimal design (power of 90% and one-sided alpha of 0.05), this study needs total 27 evaluable patients. At the first stage, 11 patients would be enrolled. If two or more among them achieve objective response, the study will go forward the second stage. At the second stage, 16 additional patients (total 27 patients) would be enrolled. Among the total 27 evaluable patients, six or more objective responses are necessary for this drug to be evaluated further in the group of R/M HNSCC

NCT ID: NCT03440151 Active, not recruiting - Clinical trials for Tongue Squamous Cell Carcinoma

Oncological Outcome of Contralateral Submental Artery Island Flap Versus Primary Closure in Tongue Squamous Cell Carcinoma

Start date: February 21, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the oncological and functional results of the contralateral submental flap with primary closure for reconstruction of tongue squamous cell carcinoma.

NCT ID: NCT03418909 Active, not recruiting - Pain Clinical Trials

Functional Outcome After Treatment for Oropharyngeal Squamous Cell Carcinoma

Start date: April 1, 2017
Phase:
Study type: Observational

To investigate the treatment related effects of transoral robotic surgery (TORS) or oncological treatment of oropharyngeal squamous cell carcinoma with a 1-year follow up.

NCT ID: NCT03389477 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Start date: April 27, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the results of treating patients with HPV-unrelated head and neck squamous cell carcinoma with neoadjuvant single-agent palbociclib, followed by chemoradiation (either cisplatin + IMRT or cetuximab + IMRT depending on patient characteristics), followed by adjuvant single-agent palbociclib.

NCT ID: NCT03387111 Active, not recruiting - Clinical trials for Squamous Cell Carcinoma

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Start date: January 13, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with SCC who have progressed on or after previous platinum-based chemotherapy and anti-PD-1/PD-L1 therapy. Phase 2 will be based on Simon's two-stage optimal design.

NCT ID: NCT03386357 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Radiotherapy With Pembrolizumab in Metastatic HNSCC

Start date: July 20, 2018
Phase: Phase 2
Study type: Interventional

Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma.

NCT ID: NCT03381183 Active, not recruiting - Clinical trials for Squamous Cell Carcinoma

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Start date: August 21, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to see if the IRX-2 regimen and Durvalumab, will have a tolerable safety profile and will increase the intratumoral immune profile compared with the pretreatment tumors.

NCT ID: NCT03377400 Active, not recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Start date: December 14, 2017
Phase: Phase 2
Study type: Interventional

This is a single arm phase II study, in which 2 cycles of chemotherapy (5FU/CDDP) and immunotherapy (durvalumab and tremelimumab) are administered every 3 weeks with concurrent radiotherapy for inoperable locally advanced esophageal squamous cell carcinoma. Four weeks after completion of CCRT combined with immunotherapy, 2 cycles of durvaluma and tremelimumab will be administered every 4 weeks and thereafter durvalumab monotherapy Q4W will be maintained until unacceptable toxicity or disease progression, or for maximum 2 years after enrollment.

NCT ID: NCT03370276 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Start date: December 20, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find out if the combination of two established anti-cancer therapies are beneficial in participants with Head and Neck Squamous Cell Carcinoma (HNSCC). Specifically, investigators want to determine if the combination of Cetuximab and nivolumab can help people with advanced cases of HNSCC. Both cetuximab and nivolumab have been used separately to treat HNSCC and are Food and Drug Administration (FDA) approved in this type of cancer.